Skip to main content

Advertisement

Table 2 MPN-SAF 10-item symptoms reported by MPN within the last 12 monthsa

From: Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

  MF (n = 207) PV (n = 380) ET (n = 226)
Symptom Mean Score Incidence, % Mean Score Incidence, % Mean Score Incidence, %
Fatigueb 5.1 80 4.6 73 4.3 71
Abdominal discomfort 2.3 53 1.4 35 1.3 31
Night sweatsc 2.3 51 2.0 45 1.9 38
Early satiety 2.0 37 1.1 22 1.0 21
Bone paind 2.0 40 1.2 23 1.2 27
Inactivity 1.9 31 1.5 24 1.0 19
Itching 1.8 40 2.9 55 1.4 33
Weight loss 1.6 28 0.5 12 0.5 10
Concentration problems 1.5 29 2.0 36 1.9 35
Fever 0.6 14 0.2 5 0.2 6
MPN-SAF TSS 21.2 NA 17.4 NA 14.8 NA
  1. ET = essential thrombocythemia; MF = myelofibrosis; MPN = myeloproliferative neoplasm; MPN-SAF TSS = Myeloproliferative Neoplasm Symptom Assessment Form 10-item total symptom score; NA = not applicable; PV = polycythemia vera
  2. aThis table summarizes only those symptoms included in the MPN-SAF 10-item instrument and is not inclusive of all symptoms that were assessed in the MPN Landmark survey. Symptom severity score was on a scale of 0 (absent) to 10 (worst imaginable); mean scores included in this table were calculated among those respondents who reported experiencing the symptom (ie, score ≥1) within the 12 months preceding the survey
  3. bPresented as “fatigue” to respondents with MF and PV and as “fatigue and tiredness” to respondents with ET
  4. cPresented as “night sweats” to respondents with MF and ET and as “day and night sweats” to respondents with PV
  5. dDiffuse, not joint pain or arthritis